德康医疗

最新新闻

• 公司公告
  DexCom | 4: Statement of changes in beneficial ownership of securities-Director Ashley Euan A.
  SEC · 2025/10/29
• 评级变动
  Truist Financial Maintains DexCom(DXCM.US) With Buy Rating, Maintains Target Price $102
  \u5e02\u573a\u8d44\u8baf · 2026/9/24
• 公司公告
  DexCom | 4: Statement of changes in beneficial ownership of securities-Director Ashley Euan A.
  SEC · 2026/6/2
• 评级变动
  Citi Maintains DexCom(DXCM.US) With Buy Rating, Raises Target Price to $105
  \u5e02\u573a\u8d44\u8baf · 2026/8/14
• 评级变动
  Truist Financial Maintains DexCom(DXCM.US) With Buy Rating, Raises Target Price to $102
  \u5e02\u573a\u8d44\u8baf · 2026/9/18
• 评级变动
  A Quick Look at Today's Ratings for DexCom(DXCM.US), With a Forecast Between $82 to $105
  \u5e02\u573a\u8d44\u8baf · 2026/7/31
• Barclays Initiates DexCom(DXCM.US) With Buy Rating, Announces Target Price $115
  \u5e02\u573a\u8d44\u8baf · 2026/10/8
• 公司公告
  DexCom | SC 13G/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-BlackRock, Inc.(10.4%)
  SEC · 2024/12/7
• 评级变动
  TD Cowen Maintains DexCom(DXCM.US) With Buy Rating, Maintains Target Price $95
  \u5e02\u573a\u8d44\u8baf · 2026/9/18
• 评级变动
  Mizuho Securities Maintains DexCom(DXCM.US) With Buy Rating, Maintains Target Price $95
  \u5e02\u573a\u8d44\u8baf · 2026/8/4
• RBC Capital Maintains DexCom(DXCM.US) With Buy Rating, Raises Target Price to $105
  \u5e02\u573a\u8d44\u8baf · 2026/10/1
• Citi Maintains DexCom(DXCM.US) With Buy Rating, Maintains Target Price $105
  \u5e02\u573a\u8d44\u8baf · 2026/10/5
• Barclays Upgrades DexCom(DXCM.US) to Buy Rating, Raises Target Price to $115
  \u5e02\u573a\u8d44\u8baf · 2026/10/7
• 公司公告
  DexCom | SC 13G/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-BlackRock, Inc.(8.5%)
  SEC · 2024/1/26
• 评级变动
  A Quick Look at Today's Ratings for DexCom(DXCM.US), With a Forecast Between $82 to $94
  \u5e02\u573a\u8d44\u8baf · 2026/8/1
• 公司公告
  DexCom | 3: Initial statement of beneficial ownership of securities-Director Ashley Euan A.
  SEC · 2025/10/29
• 评级变动
  Argus Research Maintains DexCom(DXCM.US) With Buy Rating, Raises Target Price to $96
  \u5e02\u573a\u8d44\u8baf · 2026/8/4
• 评级变动
  CCORF Maintains DexCom(DXCM.US) With Buy Rating, Raises Target Price to $90
  \u5e02\u573a\u8d44\u8baf · 2026/8/3
• RBC Capital Initiates DexCom(DXCM.US) With Buy Rating, Announces Target Price $105
  \u5e02\u573a\u8d44\u8baf · 2026/10/3
• 评级变动
  Wells Fargo Maintains DexCom(DXCM.US) With Buy Rating, Maintains Target Price $90
  \u5e02\u573a\u8d44\u8baf · 2026/9/30
• 评级变动
  UBS Maintains DexCom(DXCM.US) With Buy Rating, Raises Target Price to $96
  \u5e02\u573a\u8d44\u8baf · 2026/7/29
• 评级变动
  Mizuho Securities Maintains DexCom(DXCM.US) With Buy Rating, Raises Target Price to $90
  \u5e02\u573a\u8d44\u8baf · 2026/7/15
• 评级变动
  Truist Financial Maintains DexCom(DXCM.US) With Buy Rating, Announces Target Price $87
  \u5e02\u573a\u8d44\u8baf · 2026/7/16
• 评级变动
  RBC Capital Maintains DexCom(DXCM.US) With Buy Rating, Maintains Target Price $85
  \u5e02\u573a\u8d44\u8baf · 2026/7/14
• Citi Maintains DexCom(DXCM.US) With Buy Rating, Maintains Target Price $105
  \u5e02\u573a\u8d44\u8baf · 2026/8/14

新闻标题为自动聚合内容，未经我们团队独立核实或编辑。